FDA · What's New Related to Drugs· FDA·· 5 小时前AI 评分38
FDA向Guangzhou Jiugong Research And Development Biotechnology Co., Ltd.发出警告信：涉及非处方药色素及CGMP违规
Guangzhou Jiugong Research And Development Biotechnology Co., Ltd. - 737769 - 10/27/2026
AI 导读
FDA向Guangzhou Jiugong Research And Development Biotechnology Co., Ltd.发出警告信，指出其非处方药存在CGMP违规。涉事产品标签列有已撤销许可的色素FD&C Red No. 2，且与配方及检验报告不一致；FDA要求提交质量部门全面评估及整改计划。
来源：FDA · What's New Related to Drugs · fda.gov